The robust anti-cancer effects of Eg5 suppression seen across diverse preclinical cancer models spurred the discovery and development of numerous Eg5 inhibitors, including but not limited to monastrol, Ispinesib, SB-743921, and Arry-520 (Filanesib). Here, KIF11 is linked to cancer.